论文部分内容阅读
抗血管新生的新策略应具有最大的抗血管生成效率,同时对当前血管新生抑制物有最小抵抗。抗PLGF抗体(αPLGF)调节病理性血管新生,但是不影响生理性血管新生,而且αPLGF抑制许多肿瘤的生长和转移,包括对αVEGF抵抗的肿瘤,增强化疗药物和αVEGF的疗效。和αVEGF不同的是,αPLGF阻止血管新生巨噬细胞的渗透和肿瘤的严重缺氧,因此不产生拮抗αVEGF的血管新生营救机制,而且不引起或者增强αVEGF相关的副作用。αPLGF的效率和安全性以及可忽略的血管新生营救机制表明αPLGF可能是治疗癌症的一种新方法。
The new antiangiogenic strategy should have the greatest anti-angiogenic efficiency with minimal resistance to current angiogenesis inhibitors. Anti-PLGF antibodies (αPLGF) regulate pathological angiogenesis but do not affect physiological angiogenesis, and αPLGF inhibits the growth and metastasis of many tumors, including αVEGF-resistant tumors, enhancing chemotherapeutic drugs and αVEGF. Unlike αVEGF, αPLGF blocks the infiltration of angiogenic macrophages and severe hypoxia in tumors and therefore does not produce angiogenic rescue mechanisms that antagonize αVEGF and does not cause or enhances αVEGF-related side effects. The efficiency and safety of [alpha] PLGF as well as negligible angiogenic rescue mechanisms suggest that [alpha] PLGF may be a new approach to the treatment of cancer.